Valbenazine vs deutetrabenazine?

Here’s a concise side-by-side of valbenazine and deutetrabenazine, two VMAT2 inhibitors used for tardive dyskinesia (TD):

What they are
- Both inhibit vesicular monoamine transporter 2 (VMAT2) to reduce abnormal, involuntary movements in TD.

Brand names
- Valbenazine: Ingrezza
- Deutetrabenazine: Austedo

Dosing and how often you take them
- Valbenazine (Ingrezza)
- Dosing is once daily.
- Typical maintenance dose: 80 mg once daily after a 40 mg daily start for 1 week.
- Maximum: 80 mg per day.
- Deutetrabenazine (Austedo)
- Dosing is twice daily (divided dosing).
- Start: usually 6 mg twice daily (12 mg/day).
- Titrate up weekly by 6 mg per dose (12 mg/day total per week) as tolerated.
- Typical target range: up to 24 mg twice daily (48 mg/day) is common; maximum often listed as 48 mg/day.

Key pharmacokinetic differences
- Valbenazine: longer-acting formulation; designed for once-daily dosing.
- Deutetrabenazine: uses deuterium substitution to slow metabolism; still given twice daily due to shorter overall half-life despite deuteration.

Metabolism and drug interactions to know
- Both are metabolized by liver enzymes (cytochrome P450 system, notably CYP2D6 and CYP3A4 pathways). Because of this, strong inhibitors or inducers of these enzymes can affect levels and may require dose adjustments.
- Practical point: clinicians watch for drug interactions with antidepressants (e.g., SSRIs that affect CYP2D6) and other meds that affect liver enzymes.

Common side effects and safety considerations
- Similar adverse effects: somnolence/fatigue, headache, nausea, dry mouth, and movement-related side effects like akathisia can occur.
- QT prolongation risk: both have potential to affect the heart’s rhythm, so monitoring may be advised if you’re on other QT-prolonging meds or have heart rhythm concerns.
- Mood/depression and suicidality: VMAT2 inhibitors carry a warning about mood changes; monitor for worsening depression or suicidality.
- Hepatic function and other health issues: dosing may be adjusted if liver function is impaired; a clinician will tailor dosing accordingly.

Practical differences (when to prefer one over the other)
- Adherence and lifestyle: if you prefer once-daily dosing, valbenazine may be more convenient.
- Dose ceiling: valbenazine allows a higher daily dose (up to 80 mg) than deutetrabenazine (commonly up to 48 mg/day), which can be relevant for TD symptoms in some patients.
- Drug interactions: since deutetrabenazine is well studied with CYP2D6 inhibitors and in poorer metabolizers, some clinicians prefer it when drug interactions are a concern; others may choose valbenazine depending on other meds.
- Titration speed: deutetrabenazine involves a careful weekly titration schedule; valbenazine has a simpler start (40 mg then 80 mg) but still requires monitoring for side effects.

Bottom line
- Both are effective for tardive dyskinesia but differ in dosing schedule, maximum daily dose, and some pharmacokinetic and interaction profiles.
- Choice depends on: TD severity, other medications (and potential drug interactions), liver function, adherence considerations (once daily vs twice daily), and how your clinician weighs the risk/benefit of the higher max dose with valbenazine versus the dose-capped approach with deutetrabenazine.

If you want, tell me about:
- Your current TD symptoms and any TD rating scale scores
- Other meds you’re taking (especially CYP2D6 or CYP3A4 inhibitors/inducers)
- Any liver issues or heart rhythm concerns
- Preference for once-daily vs twice-daily dosing

I can tailor a more precise side-by-side or help you interpret which might be more suitable with your situation.